pentobarbital will decrease the extent or influence of trazodone by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Watch.
pentobarbital and olopatadine intranasal both increase sedation. Prevent or Use Alternate Drug. Coadministration increases chance of CNS despair, which can cause additive impairment of psychomotor performance and lead to daytime impairment.
Monitor Closely (1)pentobarbital will lessen the extent or impact of benzhydrocodone/acetaminophen by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Keep track of Closely. Caution when discontinuing CYP3A4 inducers which have been coadministered with benzhydrocodone (prodrug of hydrocodone); plasma concentrations of hydrocodone might enhance and may result in possibly lethal respiratory despair.
pentobarbital will lessen the extent or outcome of lumefantrine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration with strong CYP3A4 inducers can lead to reduced serum concentrations and loss of antimalarial efficacy
pentobarbital will lower the level or effect of irinotecan by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
pentobarbital will decrease the level or result of tamoxifen by impacting hepatic enzyme CYP2C9/ten metabolism. Use Warning/Observe.
CYP3A4 inducers could raise the development from the neurotoxic/nephrotoxic ifosfamide metabolite, chloroacetaldehyde. Carefully observe patients using ifosfamide with CYP3A4 inducers for toxicities and think about dose adjustment.
pentobarbital will lessen the level or effect of suvorexant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor. Strong CYP3A4 inducers may decrease suvorexant efficacy; if increased suvorexant dose required, do not exceed 20 mg/working day
pentobarbital will reduce the level or impact of piroxicam by impacting hepatic enzyme CYP2C9/ten metabolism. Minor/Significance Unknown.
Aged or debilitated sufferers might respond to barbiturates with marked despair, enjoyment, and confusion; in some patients, barbiturates regularly produce exhilaration as an alternative to depression
pentobarbital will lessen the extent or influence of cobimetinib by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Stay clear of coadministration. Strong or moderate CYP3A inducers might reduce cobimetinib systemic exposure by >eighty% and minimize its efficacy.
Check Closely (one)pentobarbital will lessen the level or impact of glecaprevir/pibrentasvir by influencing hepatic/intestinal enzyme CYP3A4 metabolism.
Training warning when administered to people with acute or Serious click here agony; could bring about paradoxical exhilaration or critical signs and symptoms may very well be masked
pentobarbital will minimize the level or outcome of glecaprevir/pibrentasvir by affecting hepatic/intestinal enzyme CYP3A4 metabolism.